FDA approves Xolair ® (omalizumab) for people with chronic idiopathic urticaria (CIU), a form of chronic hives
2014

Until a few years ago, the only approved therapy for chronic idiopathic urticaria was H1-antihistamines; however, this treatment was not providing sufficient responses in most patients. The FDA recently implemented Xolair (omalizumab) for patients 12 years and older who are still symptomatic even after using H1-antihistamines. Since this medication option is still new, there are side effects that occur, and will hopefully decrease as more information is obtained.